1.

New Drug Application (NDA)

 Purpose:
o An NDA is submitted to the USFDA when a pharmaceutical company seeks approval to
market a new drug in the United States.
 Contents of an NDA:
o Preclinical and clinical trial data
o Drug safety and efficacy results
o Manufacturing and labeling information
 Outcome:
o If approved, the drug can be legally marketed and prescribed to patients.

2. Biologics License Application (BLA)

 Purpose:
o A BLA is submitted for biological products (e.g., vaccines, monoclonal antibodies, gene
therapy, blood products).
 Regulated by:
o FDA’s Center for Biologics Evaluation and Research (CBER)
 Key Requirements:
o Clinical trial results
o Manufacturing process and quality control
o Evidence of safety, purity, and potency
 Outcome:
o Approval allows the manufacturer to distribute the biologic product in the market.

3. Drug Master File (DMF)

 Purpose:
o A DMF contains confidential technical information about a drug's manufacturing,
chemistry, or formulation that can be referenced in multiple regulatory applications.
 Types of DMFs:
o Type I: Manufacturing site, facilities
o Type II: Drug substance, drug product, intermediates
o Type III: Packaging materials
o Type IV: Excipients, colorants, flavors
o Type V: FDA-accepted reference information
 Outcome:
o Helps multiple companies use the same supplier's data without disclosing proprietary
details.
4. Investigational New Drug Application (IND)

 Purpose:
o An IND is submitted before starting clinical trials on humans to investigate a new drug’s
safety and efficacy.
 Types of INDs:
o Commercial IND: Filed by pharmaceutical companies for drug development.
o Research (Non-Commercial) IND: Filed by academic researchers or organizations for
experimental drugs.
 Key Requirements:
o Preclinical study data (animal testing results)
o Proposed clinical trial design
o Manufacturing details
 Outcome:
o If the FDA approves the IND, clinical trials can begin in phases 1-3 before submitting an
NDA/BLA.

Slide

Feature 1: Granularity Options for All Modules (1 to 5)

"Think of eCTD like a filing cabinet with different drawers. Each drawer represents one of the
five modules of eCTD, such as administrative details, summaries, quality reports, and clinical
trial data. Each module can be further divided into smaller, more specific sections, making it
easier to access and update only the necessary parts."

📌 Example:
Imagine a company submits a drug application, and a few months later, they need to update just
one section—like the manufacturing process details. Instead of submitting the entire document
again, they can simply replace the updated section while keeping the rest unchanged.

Feature 2: PDF Documents Linked via XML Backbone

"eCTD organizes all submission files using XML, a coding structure that acts like a digital table
of contents. This means all PDFs in the submission are linked, allowing regulators to navigate
between them quickly and efficiently."

📌 Example:
Think of a website where you click on a menu option, and it takes you to a specific section.
Similarly, in eCTD, regulators can click on an index in the XML file and instantly jump to a
specific study report or manufacturing detail.
Feature 3: Increased Document Granularity

"Granularity in eCTD means breaking down large reports into smaller parts so that only
necessary sections need updating instead of re-submitting the entire file."

📌 Example:
Let’s say a pharmaceutical company is submitting a clinical trial report for a new drug. Later,
they find an error in only one table within the report. With eCTD, they can simply replace that
specific section without having to resubmit the entire document, saving time and effort.

Feature 4: Transparency in the Submission Process

"Since all files in eCTD are well-structured and easy to track, regulators can see exactly which
files were submitted, updated, or replaced, making the entire approval process transparent."

📌 Example:
Imagine submitting an assignment online. You can see when each document was uploaded, and
your teacher can track which version is the latest. Similarly, regulators can track all changes in
an eCTD submission and quickly find the most recent updates.

Feature 5: Ease of Navigation and Review

"Because eCTD is fully digital and structured, regulators don’t have to manually sift through
stacks of paper. They can instantly access the required sections, making their review process
much faster and more efficient."

📌 Example:
Imagine a doctor looking for a patient’s blood test result in a digital hospital system. Instead of
flipping through pages of a physical file, they just type the patient’s name and quickly find the
information. In the same way, eCTD helps regulators search for and access specific documents
instantly.

Slide

[Key Components]"The e-CTD is composed of various file types that serve different functions.
Text-based content, such as study reports and clinical summaries, is stored in PDF format to
ensure consistency in formatting across different devices. Meanwhile, SAS transport files are
used to store structured data, such as statistical outputs and datasets, which are crucial for
regulatory analysis."

[Core Features]
"All these documents and datasets are interconnected through an XML backbone. This XML
framework allows seamless navigation, making the e-CTD function much like a webpage, where
users can easily access different sections."

"Viewing capabilities are enhanced with features like links and bookmarks, allowing reviewers
to quickly jump to relevant sections. Additionally, the e-CTD includes a search function,
enabling users to find specific keywords and metadata within the document."

[Lifecycle Management]
"A key advantage of the e-CTD is its structured document lifecycle management. It supports
actions such as appending new files, replacing outdated content, and deleting unnecessary
documents, ensuring that the submission remains up to date without unnecessary duplication."

[Additional Notes]
"To ensure clarity, let’s briefly define two important terms. PDF, or Portable Document
Format, is a widely used file format designed to preserve text and layout. On the other hand,
SAS, or Statistical Analysis System, is a software suite used for advanced analytics, business
intelligence, and predictive modeling, making it a crucial tool in regulatory submissions."

Slide

"When submitting an e-CTD (Electronic Common Technical Document), it's crucial to follow the
technical guidelines to ensure that your submission is accepted without any issues. Let's go
through the key requirements in detail."

1) Submission Media:

"First, all e-CTD submissions must be provided on physical storage media such as CD-ROMs or
DVD-ROMs. This means you cannot submit documents through USB drives, cloud storage, or
email attachments."

"Additionally, the CDs must follow specific industry standards, such as ISO 9660 or ISO 13346.
This ensures that the data format is universally readable across different systems."

"It's also important to note that the Medical Control Council (MCC) does not accept hardware
such as laptops, desktops, or external drives for electronic submissions. Only CDs or DVDs are
allowed."

"Finally, the submission media should be securely packed to prevent damage. This means using
protective CD cases or bubble wrap to ensure the disc remains intact during transport."
"Next, let's talk about file security and compression. Applicants must ensure that files are not
compressed or encrypted. This means you should submit your documents in their original format
rather than packaging them into ZIP, RAR, or any other compressed file types."

"Additionally, password protection should not be applied to any files. This allows regulatory
authorities to easily access and review the documents without the need for special access
credentials."

Slide

Firstly, when it comes to PDF files, make sure you're using a version between 1.4 and 1.7. These
files need to be compatible with Acrobat Reader or similar software. It's best to generate PDFs
directly from electronic source documents rather than scanning paper files. This ensures better
functionality for searching, copying, and pasting text. Remember, the maximum size for a single
PDF file is 200 megabytes. If your file exceeds this limit, split it into smaller files.

Now, moving on to file naming conventions: Follow the recommendations outlined in the ICH
M2 eCTD specification or any regional guidelines If you're submitting multiple files under the
same section, add variable suffixes to filenames to differentiate them. For example, you might
name a file '[Link].'

Slide

This slide explains the Metadata requirements in the context of eCTD (electronic Common
Technical Document) submissions. Metadata refers to the structured information or data about
the submission that helps organize, classify, and navigate the application effectively within
regulatory systems.

Breakdown of Metadata:

1. Regional Information:

This section captures details that vary depending on the specific regulatory authority or region
(e.g., FDA in the U.S., EMA in Europe):

 Company Name: The name of the company submitting the application.

 Application Number: A unique identifier assigned to the submission.
 Date of Submission: When the application is officially submitted to the regulatory authority.
 Product Name and Type: The name and category/type of the product (e.g., drug, biologic).
 Application Type: The nature of the application (e.g., New Drug Application, Abbreviated New
Drug Application, etc.).
 Submission Type: Whether it is an original application, amendment, or supplemental
application.

2. ICH Information:
This section aligns with the International Council for Harmonisation (ICH) standards, which
ensure global consistency in eCTD submissions:

 Product, Dosage Form, Manufacturer, Excipient: Specifics about the product, including its form
(e.g., tablet, injection), the company manufacturing it, and the excipients used.
 Substance & Manufacturer: Information about the active pharmaceutical ingredient (API) and
its manufacturer.
 Indication: The intended use or therapeutic purpose of the product (e.g., treatment of
diabetes).
 Novel Excipient: Details if the formulation includes a new or unique excipient not previously
approved.

This metadata is a core component of eCTD Module 1 (regional information) and parts of
Modules 2-5, ensuring the application is comprehensive and user-friendly.

Slide

.eCTD Folder Structure Example

Top-Level Folder (0000)

This represents the first sequence of the submission. If there are updates or changes later, new
sequences like 0001, 0002, etc., will be created.

Folders for Each Module:

1. M1 (Regional Information)
Contains documents specific to the regulatory authority.
Example files:
o [Link] (Cover letter for the submission)
o [Link] (Administrative form)
o [Link] (Prescribing information like SmPC, PIL, labeling)

2. M2 (Common Technical Document Summaries)

Contains high-level summaries of the application.
Example files:
o [Link] (Summary of Module 3)
o [Link] (Summary of Module 4)
o [Link] (Summary of Module 5)

3. M3 (Quality)
Includes detailed information about the drug substance and drug product.
Example files:
o [Link]
o [Link]
 o [Link]

4. M4 (Nonclinical Study Reports)

Contains pharmacology and toxicology study reports.
Example files:
o [Link]
o [Link]
o [Link]

5. M5 (Clinical Study Reports)

Contains reports of clinical trials.
Example files:
o [Link]
o [Link]
o [Link]

Util Folder:

This folder contains technical and utility files needed to view and validate the submission.
Example files:

 [Link] (Defines the XML structure)

 [Link] (Stylesheet for viewing XML data)

Key Files:

 [Link]:
o Acts as the central navigation file for the submission.
o Contains links to all the documents in the structure.
 [Link]:
o Used to check file integrity and ensure that files haven't been altered during submission.

Slide

Regulatory authorities like the FDA (USA), EMA (Europe), PMDA (Japan), and TGA
(Australia) use XML in eCTD submissions for efficient drug approval processes. Here’s how
they use it:

1️⃣ Organizing Drug Submission Data

XML acts like a table of contents for the eCTD. It helps regulatory agencies navigate
thousands of documents easily.

🔹 Without XML:
Imagine a huge pile of paper documents sent to FDA—very difficult to manage.

🔹 With XML:
All documents are digitally indexed, linked, and categorized, making them easy to access.

📂 Example of XML Indexing in eCTD:

<ectd>
<module1>
<document>
<title>Cover Letter</title>
<file>[Link]</file>
</document>
</module1>
<module5>
<document>
<title>Phase 3 Clinical Trial Report</title>
<file>[Link]</file>
</document>
</module5>
</ectd>

✅ This tells the FDA where the cover letter and clinical trial data are stored without
manually searching.

2️⃣ Automating Validation & Compliance Checks

Before reviewing a drug application, authorities automatically validate the submission using
XML.

✅ Regulatory authorities check for:

✔️Correct folder structure (Modules 1–5 in eCTD format)
✔️File integrity (Are documents missing or corrupted?)
✔️Compliance with guidelines (Does it follow ICH eCTD rules?)

⚠️Example of an Error in eCTD Submission:

If a required document (like a clinical trial report) is missing, XML will flag the error
automatically.

3️⃣ Faster Review & Decision Making

Regulatory reviewers don’t manually open each PDF—instead, they use software that reads
XML to:
🔎 Quickly find and filter data (e.g., all safety reports)
📊 Compare different submissions (e.g., Phase 1 vs. Phase 3 trial results)
📑 Search for specific keywords (e.g., side effects like "headache" or "nausea")

📌 Example – Reviewing Clinical Data Faster

Instead of searching through 100+ PDFs, the XML helps the system directly retrieve "Phase 3
Trial Adverse Effects Data."

4️⃣ Enabling Global Drug Submissions

Since all major regulatory bodies follow eCTD, pharmaceutical companies submit the same
XML-based dossier worldwide.

✅ Benefits:
🌍 One submission, multiple approvals (FDA, EMA, PMDA, etc.)
🚀 Reduces duplication of work
🔄 Easier updates and modifications (e.g., adding new safety data)

5️⃣ Facilitating Post-Market Surveillance

Even after drug approval, XML helps authorities track:

📢 Adverse drug reactions (ADR)
📊 Periodic safety updates (PSURs)
💊 Labeling changes & warnings

For example, if new side effects appear, companies submit an updated XML, and agencies
automatically compare it with previous submissions.

Summary – Why XML is Critical for Drug Approvals

🔹 Organizes thousands of regulatory documents digitally

🔹 Automates validation & compliance checks
🔹 Speeds up drug review & approval
🔹 Standardizes global submissions (FDA, EMA, PMDA, etc.)
🔹 Enables quick post-market updates

Slide
Here’s a voice-over script for the rephrased slide:

🔊 "Advantages of eCTD"

✔ Electronic Common Technical Document, or eCTD, improves the management and archiving
of submissions for both sponsors and the FDA.

✔ It enhances reviewer efficiency, making the assessment process faster and more streamlined.

✔ With advanced search functionality, tracking and monitoring submissions become more
effective.

✔ The eCTD format allows documents to be easily repurposed for regulatory submissions
across different regions.

✔ It also ensures seamless accessibility to documents within various modules, enhancing

collaboration and compliance.

✔ Finally, submission through the Electronic Submission Gateway, or ESG, enables instant
receipt by the FDA, ensuring a smooth and secure transmission of regulatory information.

🎤 This structured approach enhances regulatory compliance while making submissions more
efficient and accessible.